SSR 150106

Drug Profile

SSR 150106

Alternative Names: SSR150106; SSR150106XB

Latest Information Update: 13 May 2008

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Anti-inflammatories
  • Mechanism of Action CCR2 receptor antagonists; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 13 Feb 2007 Phase-II clinical trials in Inflammation in Europe (unspecified route)
  • 01 Mar 2005 Phase-I clinical trials in Inflammation in Europe (unspecified route)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top